Cargando…
Addendum: Sustained response of three pediatric BRAF(V600E) mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy
Autores principales: | Toll, Stephanie A., Tran, Hung N., Cotter, Jennifer, Judkins, Alexander R., Tamrazi, Benita, Biegel, Jaclyn A., Dhall, Girish, Robison, Nathan J., Waters, Kaaren, Patel, Palak, Cooper, Robert, Margol, Ashley S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197959/ https://www.ncbi.nlm.nih.gov/pubmed/37204254 http://dx.doi.org/10.18632/oncotarget.28445 |
Ejemplares similares
-
Sustained response of three pediatric BRAF(V600E) mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy
por: Toll, Stephanie A., et al.
Publicado: (2019) -
Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report
por: Rao, Mayank, et al.
Publicado: (2023) -
Transmission of a TP53 germline mutation from unaffected male carrier associated with pediatric glioblastoma in his child and gestational choriocarcinoma in his female partner
por: Cotter, Jennifer A., et al.
Publicado: (2018) -
Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas
por: Fusco, Michael J., et al.
Publicado: (2021) -
Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)